• Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

  • Sep 4 2024
  • Length: 18 mins
  • Podcast

Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

Listen for free

View show details

  • Summary

  • In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL.

    Our Guest:
    Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.

    If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com

    This episode was funded by Eli Lilly, Canada.

    Show More Show Less
Show More Show Less

What listeners say about Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available